Fig. 3: Genetic markers as moderators of treatment response. | Translational Psychiatry

Fig. 3: Genetic markers as moderators of treatment response.

From: Enhancing exposure therapy for posttraumatic stress disorder (PTSD): a randomized clinical trial of virtual reality and imaginal exposure with a cognitive enhancer

Fig. 3

Note: Genetic markers (A Val66Met and B C385A) as moderators of treatment response. BDNF Val66Met (n = 59) is Val/Met (n = 50) and Met/Met (n = 9) carriers combined, FAAH C385A (n = 80) is A/A (n = 15) and A/C carriers (n = 65) combined. d = effect sizes (Cohen’s d) for CAPS-IV, past week baseline-posttreatment change scores for those with and without the genetic marker. CAPS-IV clinician administered posttraumatic stress disorder (PTSD) scale for DSM-IV, DCS D-cycloserine, MDD major depressive disorder.

Back to article page